Cargando…

The effect of anti-angiogenic agents on overall survival in metastatic oesophago-gastric cancer: A systematic review and meta-analysis

BACKGROUND: Studies of anti-angiogenic agents (AAs), combined with chemotherapy (chemo) or as monotherapy in metastatic oesophago-gastric cancer (mOGC), have reported mixed outcomes. We undertook systematic review and meta-analysis to determine their overall benefits and harms. METHODS: Randomized c...

Descripción completa

Detalles Bibliográficos
Autores principales:	Chan, David L., Sjoquist, Katrin M., Goldstein, David, Price, Timothy J., Martin, Andrew J., Bang, Yung-Jue, Kang, Yoon-Koo, Pavlakis, Nick
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2017
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5319652/ https://www.ncbi.nlm.nih.gov/pubmed/28222158 http://dx.doi.org/10.1371/journal.pone.0172307

Ejemplares similares

Value of central review of RECIST v1.1 outcomes in the AGITG INTEGRATE randomised phase 2 international trial for advanced oesophago-gastric cancer
por: Sjoquist, Katrin M., et al.
Publicado: (2022)

A pooled analysis of molecularly targeted agents for treatment of metastatic oesophago-gastric cancer in elderly patients
por: Lv, Hui, et al.
Publicado: (2020)

The pattern of recurrence of adenocarcinoma of the oesophago-gastric junction
por: Wayman, J, et al.
Publicado: (2002)

Optimising Multimodality Treatment of Resectable Oesophago-Gastric Adenocarcinoma
por: Suwaidan, Ali Abdulnabi, et al.
Publicado: (2022)

Immune Checkpoint Inhibition in Oesophago-Gastric Carcinoma
por: Högner, Anica, et al.
Publicado: (2021)

mRNA profiling of the cancer degradome in oesophago–gastric adenocarcinoma
por: Baren, J P, et al.
Publicado: (2012)

Propofol Sedation for Oesophago-Gastro-Duodenoscopy
por: Watt, J. M., et al.
Publicado: (1999)

Re-organisation of oesophago-gastric cancer care in England: progress and remaining challenges
por: Palser, Thomas R, et al.
Publicado: (2009)

Modified Oesophago-Gastric Dissociation (M-OGD) — a technical modification
por: Coletta, Riccardo, et al.
Publicado: (2020)

ASO Author Reflections: Applications of Artificial Intelligence in Oesophago-Gastric Malignancies—Present Work and Future Directions
por: Chidambaram, Swathikan, et al.
Publicado: (2021)

Molecular effects of Lapatinib in the treatment of HER2 overexpressing oesophago-gastric adenocarcinoma
por: De Silva, Nadeera, et al.
Publicado: (2015)

Sequential FDG-PET and induction chemotherapy in locally advanced adenocarcinoma of the Oesophago-gastric junction (AEG): The Heidelberg Imaging program in Cancer of the oesophago-gastric junction during Neoadjuvant treatment: HICON trial
por: Lorenzen, Sylvie, et al.
Publicado: (2011)

Evaluating the care received by patients with oesophago-gastric (OG) cancer: the richer picture provided by linked datasets
por: Brand, Christian, et al.
Publicado: (2017)

New drug developments in metastatic gastric cancer
por: Tan, Aaron C., et al.
Publicado: (2018)

Neoadjuvant chemotherapy for carcinoma of the oesophagus and oesophago-gastric junction: a six-year experience
por: Halliday, Brian P, et al.
Publicado: (2007)

The Role of Mucin Expression in the Diagnosis of Oesophago-Gastric Cancer: A Systematic Literature Review
por: Patel, Nikhil Manish, et al.
Publicado: (2023)

Double stenting for malignant oesophago-respiratory fistula
por: Włodarczyk, Janusz, et al.
Publicado: (2016)

The rare case of oesophago-pericardial fistula secondary to pulmonary tuberculosis
por: Sidhu, Kavina Kaur, et al.
Publicado: (2022)

Feasibility of Implementation and the Impact of a Digital Prehabilitation Service in Patients Undergoing Treatment for Oesophago-Gastric Cancer
por: Moorthy, Krishna, et al.
Publicado: (2023)

Volume-outcome revisited: The effect of hospital and surgeon volumes on multiple outcome measures in oesophago-gastric cancer surgery
por: Fischer, Claudia, et al.
Publicado: (2017)

Diagnosis and treatment for gastro-oesophageal cancer in England and Wales: analysis of the National Oesophago-Gastric Cancer Audit (NOGCA) database 2012–2020
por: Pucher, Philip H, et al.
Publicado: (2023)

Psychosocial functioning in individuals with advanced oesophago-gastric cancer: a mixed methods systematic review
por: Ghiglieri, Cara, et al.
Publicado: (2023)

Understanding Potentially Preventable Mortality Following Oesophago-Gastric Cancer Surgery: Analysis of a National Audit of Surgical Mortality
por: Liu, David S., et al.
Publicado: (2023)

Plasma MIC-1 correlates with systemic inflammation but is not an independent determinant of nutritional status or survival in oesophago-gastric cancer
por: Skipworth, R J E, et al.
Publicado: (2010)

Re-organisation of oesophago-gastric cancer services in England and Wales: a follow-up assessment of progress and remaining challenges
por: Groene, Oliver, et al.
Publicado: (2014)

Does the Chemotherapy Backbone Impact on the Efficacy of Targeted Agents in Metastatic Colorectal Cancer? A Systematic Review and Meta-Analysis of the Literature
por: Chan, David L., et al.
Publicado: (2015)

Docetaxel combined with irinotecan or 5-fluorouracil in patients with advanced oesophago-gastric cancer: a randomised phase II study
por: Roy, A, et al.
Publicado: (2012)

Evaluating the role of fluorodeoxyglucose positron emission tomography-computed tomography in multi-disciplinary team recommendations for oesophago-gastric cancer
por: Blencowe, N S, et al.
Publicado: (2013)

Correction: Does the Chemotherapy Backbone Impact on the Efficacy of Targeted Agents in Metastatic Colorectal Cancer? A Systematic Review and Meta-Analysis of the Literature
por: Chan, David L., et al.
Publicado: (2015)

INTEGRATE II: randomised phase III controlled trials of regorafenib containing regimens versus standard of care in refractory Advanced Gastro-Oesophageal Cancer (AGOC): a study by the Australasian Gastro-Intestinal Trials Group (AGITG)
por: Lam, Lyn Ley, et al.
Publicado: (2023)

Research protocol for a diagnostic study of non-invasive exhaled breath analysis for the prediction of oesophago-gastric cancer
por: Markar, Sheraz R, et al.
Publicado: (2016)

Machine Learning for Risk Prediction of Oesophago-Gastric Cancer in Primary Care: Comparison with Existing Risk-Assessment Tools
por: Briggs, Emma, et al.
Publicado: (2022)

Anti-Angiogenic Therapy in ALK Rearranged Non-Small Cell Lung Cancer (NSCLC)
por: Tan, Aaron C., et al.
Publicado: (2022)

ICORG 10-14: NEOadjuvant trial in Adenocarcinoma of the oEsophagus and oesophagoGastric junction International Study (Neo-AEGIS)
por: Reynolds, JV, et al.
Publicado: (2017)

SOURCE: A Registry-Based Prediction Model for Overall Survival in Patients with Metastatic Oesophageal or Gastric Cancer
por: van den Boorn, Héctor G., et al.
Publicado: (2019)

The risk of oesophago-gastric cancer in symptomatic patients in primary care: a large case–control study using electronic records
por: Stapley, S, et al.
Publicado: (2013)

Main influencing factors and health-related quality of life issues in patients with oesophago-gastric cancer – as measured by EORTC tools
por: Tomaszewski, Krzysztof A., et al.
Publicado: (2013)

Biomarker analysis of cetuximab plus oxaliplatin/leucovorin/5-fluorouracil in first-line metastatic gastric and oesophago-gastric junction cancer: results from a phase II trial of the Arbeitsgemeinschaft Internistische Onkologie (AIO)
por: Luber, Birgit, et al.
Publicado: (2011)

Clinical utility of ramucirumab in advanced gastric cancer
por: Chan, Matthew MK, et al.
Publicado: (2015)

PET/CT-tailored treatment of locally advanced oesophago-gastric junction adenocarcinoma: a report on the feasibility of the multicenter GastroPET study
por: Obermannova, Radka, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_ollml7hv76s79hjs13nllkvqis